SCHEMBL19123715

SCHEMBL19123715

Cc1ccc(OCc2ccccc2)cc1NC(=O)C(F)(F)F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.52
PDK2 Q15119 1/20 0.52
PDK3 Q15120 1/20 0.52
PDK4 Q16654 1/20 0.52
TDP1 Q9NUW8 2/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
MRGPRX4 Q96LA9 1/20 0.47
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAOB P27338 2/20 0.47
ALDH1A1 P00352 2/20 0.46
PKM P14618 2/20 0.46
MAPT P10636 2/20 0.46
CASP3 P42574 3/20 0.46
SENP7 Q9BQF6 3/20 0.46
SENP8 Q96LD8 2/20 0.46
SENP6 Q9GZR1 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
TAAR1 Q96RJ0 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17845092 0.85 PDK1 (0.49) PDK1PDK2PDK3PDK4NPC1
SCHEMBL4054181 0.84 PDK1 (0.50) PDK1PDK2PDK3PDK4NPC1
SCHEMBL22626751 0.81 NPC1 (0.50) PDK1PDK2PDK3PDK4TDP1
SCHEMBL18874270 0.81 FFAR1 (0.44) PDK1PDK2PDK3PDK4MRGPRX4
SCHEMBL17845141 0.80 PTPN1 (0.53) PDK1PDK2PDK3PDK4NPC1
SCHEMBL31440602 0.79 MEN1 (0.53) TDP1CTDSP1NPC1RAB9ASMN1; SMN2
SCHEMBL30789279 0.79 PKM (0.58) NPC1RAB9ASMN1; SMN2ALDH1A1PKM
SCHEMBL3818042 0.79 LTA4H (0.65) NPC1RAB9ASMN1; SMN2ALDH1A1CASP3
SCHEMBL14409902 0.78 GAA (0.51) RAB9APKMMAPT
SCHEMBL31440573 0.78 LMNA (0.56) TDP1CTDSP1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9845291-B2 Estrogen receptor modulators and uses thereof GENENTECH, INC. (US) 2017-12-19 US disclosed
US-20170197915-A9 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF GENENTECH, INC. (US) 2017-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197915-A9 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, ESR1, GPER1 PDK1 3782/4885PDK2 3572/4885PDK3 3720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.